Hanna G Zimmermann1, Benjamin Knier2,3, Timm Oberwahrenbrock1, Janina Behrens1, Catherina Pfuhl4, Lilian Aly2,3, Miriam Kaminski2, Muna-Miriam Hoshi2, Svenja Specovius1, René M Giess1, Michael Scheel1, Mark Mühlau2,5, Judith Bellmann-Strobl1,6, Klemens Ruprecht4, Bernhard Hemmer2,7, Thomas Korn2,3,7, Friedemann Paul1,4,6, Alexander U Brandt1. 1. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 2. Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 3. Department of Experimental Neuroimmunology, Technische Universität München, Munich, Germany. 4. Department of Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 5. TUM Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 6. Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 7. Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.
Abstract
Importance: Clinically isolated syndrome (CIS) describes a first clinical incident suggestive of multiple sclerosis (MS). Identifying patients with CIS who have a high risk of future disease activity and subsequent MS diagnosis is crucial for patient monitoring and the initiation of disease-modifying therapy. Objective: To investigate the association of retinal optical coherence tomography (OCT) results with future disease activity in patients with CIS. Design, Setting, and Participants: This prospective, longitudinal cohort study took place between January 2011 and May 2017 at 2 German tertiary referral centers. A total of 179 patients with CIS were screened (80 in Berlin and 99 in Munich). Patients underwent neurological examination, magnetic resonance imaging (MRI), and OCT. Only eyes with no previous optic neuritis were considered for OCT analysis. Main Outcomes and Measures: The primary outcome was not meeting the no evidence of disease activity (NEDA-3) criteria; secondary outcomes were MS diagnosis (by the 2010 McDonald criteria) and worsening of disability. The primary measure was OCT-derived ganglion cell and inner plexiform layer thickness; the secondary measures included peripapillary retinal nerve fiber layer thickness, inner nuclear layer thickness, and MRI-derived T2-weighted lesions. Results: A total of 97 of the 179 screened patients (54.2%) were enrolled in the study at a median of 93 (interquartile range [IQR], 62-161) days after a first demyelinating event. The median follow-up duration (Kaplan-Meier survival time) was 729 (IQR, 664-903) days. Of 97 patients with CIS (mean age 33.6 [7.9] years; 61 [62.9%] female), 58 (59%) did not meet NEDA-3 criteria during the follow-up period. A Kaplan-Meier analysis showed a significant probability difference in not meeting NEDA-3 criteria by ganglion cell and inner plexiform later thickness (thinnest vs thickest tertile: hazard ratio [HR], 3.33 [95% CI, 1.70-6.55; P < .001; log-rank P = .001). A follow-up diagnosis of MS was more likely for patients with low ganglion cell and inner plexiform layer thickness (thinnest vs thickest tertile: HR, 4.05 [95% CI, 1.93-8.50]; P < .001). Low peripapillary retinal nerve fiber layer thickness likewise indicated risk of not meeting NEDA-3 criteria (thinnest vs thickest tertile: HR, 2.46 [95% CI, 1.29-4.66]; P = .01; log-rank P = .02). Inner nuclear layer thickness and T2-weighted lesion count were not associated with not meeting NEDA-3 criteria. Conclusions and Relevance: Retinal ganglion cell and inner plexiform layer thickness might prove a valuable imaging marker for anticipating future disease activity and diagnosis of MS in patients with CIS, which can potentially support patient monitoring and initiation of disease-modifying therapy.
Importance: Clinically isolated syndrome (CIS) describes a first clinical incident suggestive of multiple sclerosis (MS). Identifying patients with CIS who have a high risk of future disease activity and subsequent MS diagnosis is crucial for patient monitoring and the initiation of disease-modifying therapy. Objective: To investigate the association of retinal optical coherence tomography (OCT) results with future disease activity in patients with CIS. Design, Setting, and Participants: This prospective, longitudinal cohort study took place between January 2011 and May 2017 at 2 German tertiary referral centers. A total of 179 patients with CIS were screened (80 in Berlin and 99 in Munich). Patients underwent neurological examination, magnetic resonance imaging (MRI), and OCT. Only eyes with no previous optic neuritis were considered for OCT analysis. Main Outcomes and Measures: The primary outcome was not meeting the no evidence of disease activity (NEDA-3) criteria; secondary outcomes were MS diagnosis (by the 2010 McDonald criteria) and worsening of disability. The primary measure was OCT-derived ganglion cell and inner plexiform layer thickness; the secondary measures included peripapillary retinal nerve fiber layer thickness, inner nuclear layer thickness, and MRI-derived T2-weighted lesions. Results: A total of 97 of the 179 screened patients (54.2%) were enrolled in the study at a median of 93 (interquartile range [IQR], 62-161) days after a first demyelinating event. The median follow-up duration (Kaplan-Meier survival time) was 729 (IQR, 664-903) days. Of 97 patients with CIS (mean age 33.6 [7.9] years; 61 [62.9%] female), 58 (59%) did not meet NEDA-3 criteria during the follow-up period. A Kaplan-Meier analysis showed a significant probability difference in not meeting NEDA-3 criteria by ganglion cell and inner plexiform later thickness (thinnest vs thickest tertile: hazard ratio [HR], 3.33 [95% CI, 1.70-6.55; P < .001; log-rank P = .001). A follow-up diagnosis of MS was more likely for patients with low ganglion cell and inner plexiform layer thickness (thinnest vs thickest tertile: HR, 4.05 [95% CI, 1.93-8.50]; P < .001). Low peripapillary retinal nerve fiber layer thickness likewise indicated risk of not meeting NEDA-3 criteria (thinnest vs thickest tertile: HR, 2.46 [95% CI, 1.29-4.66]; P = .01; log-rank P = .02). Inner nuclear layer thickness and T2-weighted lesion count were not associated with not meeting NEDA-3 criteria. Conclusions and Relevance: Retinal ganglion cell and inner plexiform layer thickness might prove a valuable imaging marker for anticipating future disease activity and diagnosis of MS in patients with CIS, which can potentially support patient monitoring and initiation of disease-modifying therapy.
Authors: Iñigo Gabilondo; Elena H Martínez-Lapiscina; Eloy Martínez-Heras; Elena Fraga-Pumar; Sara Llufriu; Santiago Ortiz; Santiago Bullich; Maria Sepulveda; Carles Falcon; Joan Berenguer; Albert Saiz; Bernardo Sanchez-Dalmau; Pablo Villoslada Journal: Ann Neurol Date: 2014-01-02 Impact factor: 10.422
Authors: W J Brownlee; D R Altmann; P Alves Da Mota; J K Swanton; K A Miszkiel; Cam Gandini Wheeler-Kingshott; O Ciccarelli; D H Miller Journal: Mult Scler Date: 2016-08-06 Impact factor: 6.312
Authors: J Kuhle; G Disanto; R Dobson; R Adiutori; L Bianchi; J Topping; J P Bestwick; U-C Meier; M Marta; G Dalla Costa; T Runia; E Evdoshenko; N Lazareva; E Thouvenot; P Iaffaldano; V Direnzo; M Khademi; F Piehl; M Comabella; M Sombekke; J Killestein; H Hegen; S Rauch; S D'Alfonso; J C Alvarez-Cermeño; P Kleinová; D Horáková; R Roesler; F Lauda; S Llufriu; T Avsar; U Uygunoglu; A Altintas; S Saip; T Menge; C Rajda; R Bergamaschi; N Moll; M Khalil; R Marignier; I Dujmovic; H Larsson; C Malmestrom; E Scarpini; C Fenoglio; S Wergeland; A Laroni; V Annibali; S Romano; A D Martínez; A Carra; M Salvetti; A Uccelli; Ø Torkildsen; K M Myhr; D Galimberti; K Rejdak; J Lycke; J L Frederiksen; J Drulovic; C Confavreux; D Brassat; C Enzinger; S Fuchs; I Bosca; J Pelletier; C Picard; E Colombo; D Franciotta; T Derfuss; Rlp Lindberg; Ö Yaldizli; L Vécsei; B C Kieseier; H P Hartung; P Villoslada; A Siva; A Saiz; H Tumani; E Havrdová; L M Villar; M Leone; N Barizzone; F Deisenhammer; C Teunissen; X Montalban; M Tintoré; T Olsson; M Trojano; S Lehmann; G Castelnovo; S Lapin; R Hintzen; L Kappos; R Furlan; V Martinelli; G Comi; S V Ramagopalan; G Giovannoni Journal: Mult Scler Date: 2015-02-13 Impact factor: 6.312
Authors: Tomas Kalincik; Gary Cutter; Tim Spelman; Vilija Jokubaitis; Eva Havrdova; Dana Horakova; Maria Trojano; Guillermo Izquierdo; Marc Girard; Pierre Duquette; Alexandre Prat; Alessandra Lugaresi; Francois Grand'Maison; Pierre Grammond; Raymond Hupperts; Celia Oreja-Guevara; Cavit Boz; Eugenio Pucci; Roberto Bergamaschi; Jeannette Lechner-Scott; Raed Alroughani; Vincent Van Pesch; Gerardo Iuliano; Ricardo Fernandez-Bolaños; Cristina Ramo; Murat Terzi; Mark Slee; Daniele Spitaleri; Freek Verheul; Edgardo Cristiano; José Luis Sánchez-Menoyo; Marcela Fiol; Orla Gray; Jose Antonio Cabrera-Gomez; Michael Barnett; Helmut Butzkueven Journal: Brain Date: 2015-09-10 Impact factor: 13.501
Authors: Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi Journal: Lancet Neurol Date: 2012-10-04 Impact factor: 44.182
Authors: J L Bennett; J de Seze; M Lana-Peixoto; J Palace; A Waldman; S Schippling; S Tenembaum; B Banwell; B Greenberg; M Levy; K Fujihara; K H Chan; H J Kim; N Asgari; D K Sato; A Saiz; J Wuerfel; H Zimmermann; A Green; P Villoslada; F Paul Journal: Mult Scler Date: 2015-02-06 Impact factor: 6.312
Authors: Imke Metz; Tim Beißbarth; David Ellenberger; Florence Pache; Lidia Stork; Marius Ringelstein; Orhan Aktas; Sven Jarius; Brigitte Wildemann; Hassan Dihazi; Tim Friede; Wolfgang Brück; Klemens Ruprecht; Friedemann Paul Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-02-02
Authors: Frederike C Oertel; Joseph Kuchling; Hanna Zimmermann; Claudia Chien; Felix Schmidt; Benjamin Knier; Judith Bellmann-Strobl; Thomas Korn; Michael Scheel; Alexander Klistorner; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-02-22
Authors: Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Bernhard Hemmer; Edward J Fox; Frederik Barkhof; Sven Schippling; Andrea Schulze; Dirk Pleimes; Christoph Pohl; Rupert Sandbrink; Gustavo Suarez; Eva-Maria Wicklein Journal: Neurology Date: 2016-08-10 Impact factor: 9.910
Authors: Laura J Balcer; Lisanne J Balk; Alexander U Brandt; Peter A Calabresi; Elena H Martinez-Lapiscina; Rachel C Nolan; Friedemann Paul; Axel Petzold; Shiv Saidha Journal: J Neuroophthalmol Date: 2018-12 Impact factor: 3.042
Authors: Ahmed Abdelhak; Andre Huss; Alexander Stahmann; Makbule Senel; Markus Krumbholz; Markus C Kowarik; Joachim Havla; Tania Kümpfel; Ingo Kleiter; Isabella Wüstinger; Uwe K Zettl; Margit Schwartz; Romy Roesler; Tim Friede; Albert C Ludolph; Ulf Ziemann; Hayrettin Tumani Journal: Contemp Clin Trials Commun Date: 2020-05-19
Authors: Natascha Schurz; Lydia Sariaslani; Patrick Altmann; Fritz Leutmezer; Christoph Mitsch; Berthold Pemp; Paulus Rommer; Tobias Zrzavy; Thomas Berger; Gabriel Bsteh Journal: Eye Brain Date: 2021-03-12